The pharmacodynamic equivalence of Orlistat 60 mg capsule. An open label, balanced, randomized, multiple-dose, cross-over pharmacodynamic end-point bioequivalence study in healthy, adult, human Asian Indian subjects under fed conditions

References

• Bray GA. Medical Consequences of Obesity. J Clin Endocrinol Metab 2004;89:2583–9
   PubMed Web of Science ®Google Scholar
• Wilborn C, Beckham J, Campbell B, et al. Obesity: prevalence, theories, medical consequences, managment, and research directions. J Int Soc Sports Nutr 2005;2:4–31
   PubMed Web of Science ®Google Scholar
• McNeely W, Benfield P. Orlistat. Drugs 1998;56:241–9
   PubMed Web of Science ®Google Scholar
• Hollywood A, Ogden J. Taking Orlistat: predicting weight loss over 6 months. J Obes 2011;2011:1–7
   Google Scholar
• Scheen AJ, Lefebvre PJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000;16:114–24
   PubMed Web of Science ®Google Scholar
• Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs 2004;24:2845–64
   Google Scholar
• Lucas KH, Kaplan-Machlis B. Orlistat -- a novel weight loss therapy. Ann Pharmacother 2001;35:314–28
   PubMed Web of Science ®Google Scholar
• Drew BS, Dixon AF, Dixon JB. Obesity mangament: update on orlistat. Vasc Health Risk Manag 2007;3:817–21
   PubMedGoogle Scholar
• Tiikkainen M, Bergholm R, Rissanen A, et al. Effect of equal weigth loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 2004;79:22–30
   PubMed Web of Science ®Google Scholar
• Shi YF, Pan CY, Hill J, Gao Y. Orlistat in the treatment of overweigth or obese Chinese patient with newly diagnosed Type 2 diabetes. Diabetic Med 2005; 22:1737–43
   PubMed Web of Science ®Google Scholar
• Ayala RM, Garrido-Marco AC, Oca-Raul MD. Safety and efficacy of low dose Orlistat (60mg) for managment of overweight and obesity individual: a 16 weeks, double blind placebo- controlled trail. J Curr Pharm Res 2012;9:37–43
   Google Scholar
• Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21:12–23
   PubMed Web of Science ®Google Scholar
• Zhi J, Moore R, Kanitra L. The effect of short Term (21- days) orlistat treament on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003;22:357–62
   PubMed Web of Science ®Google Scholar
• Guerciolini R, Radu-Radulescu L, Boldrin M, et al. Comparative evaluation of fecal fat excretion induced by Orlistat and Chitosan. Obes Res 2001;9:364–7
   PubMedGoogle Scholar
• Ahnen DJ, Guerciolini R, Hauptman J, et al. Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects. Clin Gastroenterol Hepatol 2007;5:1291–9
   PubMed Web of Science ®Google Scholar
• Al-Suwailem AK, Al-Tamimi AS, Al-Omar MA, Al-Suhibani MS. 2006 Safety and mechanism of action of Orlistat (Tetrahydrolipstatin) as the first local antiobesity drug. J Appl Sci Res 2006;2:205–8
   Google Scholar
• Xenical [package insert]. Nutely, NJ: Roche Laboratories; 2005
   Google Scholar
• Alli [package insert]. Pittsburgh, PA: GlaxoSmithKline; 2007
   Google Scholar
• Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995;35:1103–8
   PubMed Web of Science ®Google Scholar
• Hanada K, Ikemi Y, Kukita K, et al. Stereoselective first-pass metabolism of verapamil in the small Intestine and liver in rats. Drug Metab Dispos 2008;36:2037–42
   PubMed Web of Science ®Google Scholar
• Toutain PL, Bousquet-Melou A. Bioavailability and its assessment. J Vet Pharmacol Ther 2004;27:455–66
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. 2002. p 1–12. Available online at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070241.pdf, accessed 12 Aug 2012
   Google Scholar
• Benini L, Caliari S, Guidi GC, et al. Near infrared spectrometry for faecal fat measurement: Comparison with convential gravimetric and titrmetric methods. Gut 1989;30:1344–7
   PubMed Web of Science ®Google Scholar
• Van- de Kamer JH, Ten Bokkel HH, Weyers HA. Rapid method for the determination of fat in the feces. J Biol Chem 1949;177:347–55
   PubMed Web of Science ®Google Scholar
• Franck P, Sallerin JL, Schroeder H, et al. 1996 Rapid determination of fecal fat by Fourier transform infrared analysis (FTIR) with partial least-square regression and an attenuated total reflectance accessory. Clin Chem 1996;42:2015–20
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for industry. Bioanalytical method validation. 2001. p 1–25. Available online at: http://www.fda.gov/Downloads/Drugs/Guidances/ucm 070107.pdf, accessed 12 Aug 2012
   Google Scholar
• Bijoor AR, Geetha S, Venkatesh T. Fecal fat content in healthy adults by the acid steatocrit method. Indian J Clin Biochem 2004;19:20–2
   Google Scholar
• Beath SV, Willis KD, Hooley IM, et al. New method for determining fecal fat excretion in infancy. Arch Dis Child 1993;69:138–40
   PubMed Web of Science ®Google Scholar
• Splawinski J, Kuzniar J, Kurianowicz R, Wanczura P. Bioequivalence of two preparations of ticlopidine evaluated using a pharmacodynamic end point. Int J Clin Pharmacol Ther 2005;43:452–6
   PubMed Web of Science ®Google Scholar
• Erb K, De MC, Zimmermann T, et al. Pharmacodynamic equivalence and clinical trial of a new fluorocarbon-free glycerol trinitrate pump spray with low ethanol content in comparison to a fluorocarbon-containing reference spray and a fluorocarbon-free pump spray with high ethanol content. Arzneimittelforschung 1994;44:478–82
   PubMed Web of Science ®Google Scholar
• Li S. Pharmacodynamic bioequivalence testing. J Clin Pharm Ther 2012;37:497–8
   PubMed Web of Science ®Google Scholar
• Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657–80
   PubMedGoogle Scholar
• US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for industry. Dissolution testing of immediate, release solid oral dosage forms. 1997. p 1–17. Available online at: http://www.fda.gov/cder/guidance/1713bpl.pdf, accessed 12 Aug 2012
   Google Scholar
• US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products general considerations. 2003. p 1–26. Available online at: http://www.fda.gov/Downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/ucm070124.pdf, accessed 12 Aug 2012
   Google Scholar
• Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82–5
   PubMed Web of Science ®Google Scholar
• Fine KD, Fordtran JS. The effect of diarrhea on fecal fat excretion. Gastroenterology 1992;102:1936–9
   PubMed Web of Science ®Google Scholar
• Summary basis of approval of Xenical NDA no- 20-766: Roche: US-FDA; 1999. p 30–1
   Google Scholar